ReviewTherapeutic advances in endocrinology and metabolism2015
Short commentary on empagliflozin and its potential clinical impact.
Review in Therapeutic advances in endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 10 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium glucose cotransporter type 2 (SGLT2) inhibitors are a new class of drug developed to treat type 2 diabetes mellitus (T2DM). They target the kidney by reducing renal glucose reabsorption and promoting urinary glucose excretion, which reduces hyperglycemia in individuals with T2DM. The SGLT2 inhibitor empagliflozin has gained approval in the EU and in the USA for the treatment of adults with T2DM (there is no current indication in type 1 diabetes). Empagliflozin has shown a good efficacy and safety profile from clinical trials when given as monotherapy, and as an add-on therapy to other glucose-lowering agents. This short commentary reviews the key efficacy and safety data from empagliflozin phase III trials and examines the potential role this agent may have in the management of T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.